TY - JOUR
T1 - Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma
AU - The KiHAC Respiratory Medicine Group
AU - Matsumoto, Hisako
AU - Izuhara, Kenji
AU - Kanemitsu, Yoshihiro
AU - Tohda, Yuji
AU - Horiguchi, Takahiko
AU - Kita, Hideo
AU - Tomii, Keisuke
AU - Fujimura, Masaki
AU - Yokoyama, Akihito
AU - Nakano, Yasutaka
AU - Hozawa, Soichiro
AU - Ito, Isao
AU - Oguma, Tsuyoshi
AU - Izuhara, Yumi
AU - Tajiri, Tomoko
AU - Iwata, Toshiyuki
AU - Yokoyama, Tetsuji
AU - Niimi, Akio
AU - Mishima, Michiaki
AU - Nagasaki, Tadao
PY - 2017/7
Y1 - 2017/7
N2 - Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma. Therefore, efforts to develop non-invasive biomarkers for type-2/eosinophilic airway inflammation have been made during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are considered markers of type-2/eosinophilic inflammation in asthma. However, a single-marker approach has limited the ability to diagnose severe type-2/eosinophilic asthma accurately and predict disease outcomes precisely. The present article reviews the utility of FeNO and serum periostin levels in a single-marker approach and in a multiple-marker approach in identifying patients with severe type-2/eosinophilic asthma. Furthermore, based on a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC), geno-endo-phenotypes of patients were stratified into four groups according to the FeNO and serum periostin levels.
AB - Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma. Therefore, efforts to develop non-invasive biomarkers for type-2/eosinophilic airway inflammation have been made during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are considered markers of type-2/eosinophilic inflammation in asthma. However, a single-marker approach has limited the ability to diagnose severe type-2/eosinophilic asthma accurately and predict disease outcomes precisely. The present article reviews the utility of FeNO and serum periostin levels in a single-marker approach and in a multiple-marker approach in identifying patients with severe type-2/eosinophilic asthma. Furthermore, based on a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC), geno-endo-phenotypes of patients were stratified into four groups according to the FeNO and serum periostin levels.
UR - http://www.scopus.com/inward/record.url?scp=85014014177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014014177&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2017.02.003
DO - 10.1016/j.alit.2017.02.003
M3 - Review article
C2 - 28256388
AN - SCOPUS:85014014177
VL - 66
SP - 404
EP - 410
JO - Allergology International
JF - Allergology International
SN - 1323-8930
IS - 3
ER -